• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The Rise and Fall of C-Reactive Protein: Can it Predict Immune Checkpoint Inhibitor-Associated Venous Thromboembolism?

作者信息

Wang Tzu-Fei

机构信息

Department of Medicine, University of Ottawa at The Ottawa Hospital and Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.

出版信息

JACC CardioOncol. 2024 Nov 12;6(6):976-978. doi: 10.1016/j.jaccao.2024.10.001. eCollection 2024 Dec.

DOI:10.1016/j.jaccao.2024.10.001
PMID:39801645
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11711803/
Abstract
摘要

相似文献

1
The Rise and Fall of C-Reactive Protein: Can it Predict Immune Checkpoint Inhibitor-Associated Venous Thromboembolism?C反应蛋白的兴衰：它能否预测免疫检查点抑制剂相关的静脉血栓栓塞？
JACC CardioOncol. 2024 Nov 12;6(6):976-978. doi: 10.1016/j.jaccao.2024.10.001. eCollection 2024 Dec.
2
The Khorana score and venous and arterial thrombosis in patients with cancer treated with immune checkpoint inhibitors: A Danish cohort study.Khorana 评分与接受免疫检查点抑制剂治疗的癌症患者的静脉和动脉血栓形成：一项丹麦队列研究。
J Thromb Haemost. 2022 Dec;20(12):2921-2929. doi: 10.1111/jth.15883. Epub 2022 Oct 7.
3
Early Change in C-Reactive Protein and Venous Thromboembolism in Patients Treated With Immune Checkpoint Inhibitors.接受免疫检查点抑制剂治疗患者的C反应蛋白早期变化与静脉血栓栓塞
JACC CardioOncol. 2024 Nov 12;6(6):965-975. doi: 10.1016/j.jaccao.2024.09.007. eCollection 2024 Dec.
4
Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy.免疫检查点抑制剂治疗中静脉和动脉血栓栓塞的发生率、风险因素和结局。
Blood. 2021 Mar 25;137(12):1669-1678. doi: 10.1182/blood.2020007878.
5
Thromboembolism in Patients with Metastatic Urothelial Cancer Treated with Immune Checkpoint Inhibitors.免疫检查点抑制剂治疗转移性尿路上皮癌患者的血栓栓塞事件。
Target Oncol. 2022 Sep;17(5):563-569. doi: 10.1007/s11523-022-00905-x. Epub 2022 Aug 20.
6
Thrombotic Complications Associated with Immune Checkpoint Inhibitors.与免疫检查点抑制剂相关的血栓性并发症
Cancers (Basel). 2021 Sep 14;13(18):4606. doi: 10.3390/cancers13184606.
7
Risk factors for cancer-associated thrombosis in patients undergoing treatment with immune checkpoint inhibitors.接受免疫检查点抑制剂治疗的癌症相关血栓形成患者的风险因素。
Invest New Drugs. 2020 Aug;38(4):1200-1206. doi: 10.1007/s10637-019-00881-6. Epub 2019 Dec 10.
8
The value of performance status in predicting venous thromboembolism in lung cancer patients treated with immune checkpoint inhibitors.在接受免疫检查点抑制剂治疗的肺癌患者中，体能状态评分预测静脉血栓栓塞的价值。
Eur J Oncol Nurs. 2024 Apr;69:102527. doi: 10.1016/j.ejon.2024.102527. Epub 2024 Feb 5.
9
Incidence of venous thromboembolism and discriminating capacity of Khorana score in lung cancer patients treated with immune checkpoint inhibitors.免疫检查点抑制剂治疗肺癌患者的静脉血栓栓塞发生率和 Khorana 评分的鉴别能力。
J Thromb Thrombolysis. 2022 Aug;54(2):287-294. doi: 10.1007/s11239-022-02649-x. Epub 2022 Apr 8.
10
Immune Checkpoint Inhibitors-Associated Thrombosis: Incidence, Risk Factors and Management.免疫检查点抑制剂相关血栓形成：发生率、危险因素和管理。
Curr Oncol. 2023 Mar 4;30(3):3032-3046. doi: 10.3390/curroncol30030230.

本文引用的文献

1
Immune Checkpoint Inhibitors-Associated Thrombosis: Incidence, Risk Factors and Management.免疫检查点抑制剂相关血栓形成：发生率、危险因素和管理。
Curr Oncol. 2023 Mar 4;30(3):3032-3046. doi: 10.3390/curroncol30030230.
2
C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer.C 反应蛋白升高可预测非小细胞肺癌对检查点抑制剂治疗的反应。
J Immunother Cancer. 2022 Mar;10(3). doi: 10.1136/jitc-2021-004024.
3
Thrombotic Complications Associated with Immune Checkpoint Inhibitors.与免疫检查点抑制剂相关的血栓性并发症
Cancers (Basel). 2021 Sep 14;13(18):4606. doi: 10.3390/cancers13184606.
4
Impact of C-reactive protein flare-response on oncological outcomes in patients with metastatic renal cell carcinoma treated with nivolumab.C-反应蛋白flare 反应对接受纳武利尤单抗治疗的转移性肾细胞癌患者肿瘤学结局的影响。
J Immunother Cancer. 2021 Feb;9(2). doi: 10.1136/jitc-2020-001564.
5
American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer.美国血液学会 2021 年静脉血栓栓塞症管理指南：癌症患者的预防和治疗。
Blood Adv. 2021 Feb 23;5(4):927-974. doi: 10.1182/bloodadvances.2020003442.
6
Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy.免疫检查点抑制剂治疗中静脉和动脉血栓栓塞的发生率、风险因素和结局。
Blood. 2021 Mar 25;137(12):1669-1678. doi: 10.1182/blood.2020007878.
7
Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence.根据美国国立综合癌症网络（NCCN）指南及证据水平对美国食品药品监督管理局（FDA）批准的免疫检查点抑制剂适应症的综述。
Cancers (Basel). 2020 Mar 20;12(3):738. doi: 10.3390/cancers12030738.
8
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update.静脉血栓栓塞症预防和治疗癌症患者：ASCO 临床实践指南更新。
J Clin Oncol. 2020 Feb 10;38(5):496-520. doi: 10.1200/JCO.19.01461. Epub 2019 Aug 5.
9
Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs.评估有资格接受和对检查点抑制剂免疫治疗药物有反应的美国癌症患者的百分比。
JAMA Netw Open. 2019 May 3;2(5):e192535. doi: 10.1001/jamanetworkopen.2019.2535.
10
Thromboinflammation: challenges of therapeutically targeting coagulation and other host defense mechanisms.血栓炎症：治疗性靶向凝血和其他宿主防御机制的挑战。
Blood. 2019 Feb 28;133(9):906-918. doi: 10.1182/blood-2018-11-882993. Epub 2019 Jan 14.